NKGen Biotech Partners with HekaBio to Accelerate Troculeucel Development in Japan

Shots: NKGen Biotech has partnered with HekaBio to accelerate the regulatory, manufacturing & commercial development of troculeucel in Japan As per the collaboration, HekaBio will lead trials & handle regulatory activities with Japan’s PMDA for pre-market approval of troculeucel in neurodegenerative diseases, incl. Alzheimer’s & Parkinson’s. Also, HekaBio aims for first pts dosing in Japan…

ByRidhi RastogiJuly 18, 2025

NEWS

Nicox and Kowa Enter a Licensing Agreement for NCX 470 to Treat Glaucoma

Shots: Nicox has granted Kowa exclusive global rights to develop & commercialize NCX 470 for glaucoma or ocular hypertension, excl. territories already licensed to Ocumension (China, Korea & Southeast Asia) & to Kowa (Japan) As per the deal, Nicox will receive $8.7M (€7.5M) upfront & near-term milestones tied to positive topline P-III (Denali) trial data…

ByRidhi RastogiJuly 17, 2025

NEWS

JCR Pharmaceuticals Collaborates with Acumen Pharmaceuticals to Develop Novel Alzheimer’s Therapies

Shots: JCR & Acumen have entered into a joint collaboration, option, & license agreement to develop a novel therapy to treat Alzheimer’s disease leveraging JCR’s J-Brain Cargo tech As per the deal, JCR will receive an upfront payment & an option payment if Acumen exercises its exclusive option to develop, manufacture, & commercialize up to…

ByRidhi RastogiJuly 16, 2025

NEWS

Debiopharm Enters a ~$267M Licensing Deal with Repare Therapeutics for Lunresertib

Shots: Debiopharm has entered into an exclusive global licensing agreement with Repare Therapeutics for lunresertib (PKMYT1 inhibitor) to treat difficult-to-treat solid tumors As per the deal, Repare will receive $10M upfront, ~$257M in clinical, regulatory, commercial & sales milestones, incl. $5M in near-term payments & net sales-based single-digit royalties Debiopharm will assume sponsorship of P-I (MYTHIC)…

ByRidhi RastogiJuly 16, 2025

NEWS

Otsuka Pharmaceutical Acquires CAN10 Immunology Program from Cantargia for ~$613M

Shots: Otsuka Pharmaceutical has entered into an agreement with Cantargia for the acquisition of all assets related to its P-I IL-1RAP antagonist program, CAN10 Otsuka Pharmaceutical will handle global development, regulatory approvals, manufacturing, & commercialization of CAN10. Otsuka has also acquired 3G5 as a backup antibody & holds exclusive negotiation right for next-gen IL-1RAP antibodies…

ByRidhi RastogiJuly 15, 2025

NEWS

Sun Pharma Launches Leqselvi (Deuruxolitinib) to Treat Severe Alopecia Areata in the US

Shots: Sun Pharma has launched Leqselvi (deuruxolitinib; 8mg) for the treatment of pts with severe alopecia areata in the US FDA Approval was based on 2 P-III (THRIVE-AA1 & THRIVE-AA2) trials that assessed the scalp hair regrowth using the SALT score with Leqselvi (8 or 12mg, BID) vs PBO in adults (n=1223; 18-65yrs.) with severe alopecia areata…

ByDipanshu DixitJuly 15, 2025

NEWS

BI Collaborates with LEO Pharma to Commercialize & Develop Spevigo

Shots: LEO Pharma has entered into an exclusive global license & transfer agreement with BI to commercialize & advance the development of Spevigo (spesolimab) As per the deal, LEO Pharma will handle commercialization & further development of Spevigo in exchange for $105.18M (€90M) upfront, along with milestones & tiered royalties; closing expected in H2’25, subject…

ByRidhi RastogiJuly 14, 2025

WEEKLY SNAPSHOT

PharmaShots Weekly Snapshots (Jul 07, 2025 – Jul 11, 2025)   

This week, PharmaShots’ news was all about the updates on clinical trials, Regulatory, Pharma, MedTech, M&A, and Biosimilars. Check out our full report below:  PulseSight Therapeutics Reports First Patient Dosing with PST-611 in P-I (PST-611-CT1) Trial for Dry AMD/Geographic Atrophy  Read More: PulseSight Therapeutics BioAtla Presents Preliminary P-I Trial Data of BA3182 in Patients with…

ByRidhi RastogiJuly 11, 2025

NEWS

Eolas Therapeutics Joins Forces with AstraZeneca to Develop AZD4041

Shots: Eolas Therapeutics has secured full development rights from AstraZeneca for AZD4041 to treat opioid use disorder (OUD) and other substance use disorders; terms remain confidential As per the agreement, Eolas will take full responsibility for AZD4041 under the existing IND and advance it to P-II trials with NIDA UG3 support, focusing on a patient-centered…

ByDipanshu DixitJuly 11, 2025

NEWS

AbbVie Enters a Licensing Deal with IGI Therapeutics for ISB 2001

Shots: AbbVie and IGI Therapeutics, a subsidiary of Ichnos Glenmark Innovation, have entered into an exclusive licensing deal for ISB 2001, a drug targeting oncology & autoimmune diseases developed using IGI's proprietary BEAT protein platform As per the deal, AbbVie will obtain exclusive rights to develop, manufacture, and commercialize ISB 2001 across North America, Europe,…

ByDipanshu DixitJuly 11, 2025

NKGen Biotech Partners with HekaBio to Accelerate Troculeucel Development in Japan

Nicox and Kowa Enter a Licensing Agreement for NCX 470 to Treat Glaucoma

JCR Pharmaceuticals Collaborates with Acumen Pharmaceuticals to Develop Novel Alzheimer’s Therapies

Debiopharm Enters a ~$267M Licensing Deal with Repare Therapeutics for Lunresertib

Otsuka Pharmaceutical Acquires CAN10 Immunology Program from Cantargia for ~$613M

Sun Pharma Launches Leqselvi (Deuruxolitinib) to Treat Severe Alopecia Areata in the US

BI Collaborates with LEO Pharma to Commercialize & Develop Spevigo

PharmaShots Weekly Snapshots (Jul 07, 2025 – Jul 11, 2025)

Eolas Therapeutics Joins Forces with AstraZeneca to Develop AZD4041

AbbVie Enters a Licensing Deal with IGI Therapeutics for ISB 2001

Contact US

FOLLOW US